Nebula Research & Development LLC Reduces Stock Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Nebula Research & Development LLC reduced its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 6.1% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 12,056 shares of the specialty pharmaceutical company’s stock after selling 788 shares during the period. Nebula Research & Development LLC’s holdings in ANI Pharmaceuticals were worth $666,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. JPMorgan Chase & Co. grew its stake in ANI Pharmaceuticals by 159.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 554,835 shares of the specialty pharmaceutical company’s stock valued at $33,101,000 after purchasing an additional 340,854 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its stake in ANI Pharmaceuticals by 14.6% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 15,442 shares of the specialty pharmaceutical company’s stock valued at $854,000 after acquiring an additional 1,972 shares during the last quarter. Franklin Resources Inc. boosted its stake in ANI Pharmaceuticals by 6.1% during the 3rd quarter. Franklin Resources Inc. now owns 12,057 shares of the specialty pharmaceutical company’s stock valued at $705,000 after acquiring an additional 691 shares during the last quarter. Barclays PLC boosted its stake in ANI Pharmaceuticals by 1,681.2% during the 3rd quarter. Barclays PLC now owns 143,033 shares of the specialty pharmaceutical company’s stock valued at $8,534,000 after acquiring an additional 135,003 shares during the last quarter. Finally, Victory Capital Management Inc. boosted its stake in ANI Pharmaceuticals by 6.6% during the 4th quarter. Victory Capital Management Inc. now owns 13,777 shares of the specialty pharmaceutical company’s stock valued at $762,000 after acquiring an additional 858 shares during the last quarter. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on ANIP. StockNews.com downgraded shares of ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, April 24th. Guggenheim restated a “buy” rating and issued a $86.00 price target on shares of ANI Pharmaceuticals in a research report on Friday, April 11th. HC Wainwright restated a “buy” rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a research report on Monday, March 17th. Jefferies Financial Group began coverage on shares of ANI Pharmaceuticals in a research report on Friday, March 14th. They issued a “buy” rating and a $80.00 price target on the stock. Finally, Truist Financial raised their price target on shares of ANI Pharmaceuticals from $62.00 to $65.00 and gave the stock a “hold” rating in a research report on Monday, April 21st. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $80.13.

ANI Pharmaceuticals Stock Up 1.3 %

ANI Pharmaceuticals stock opened at $70.75 on Tuesday. The stock has a market cap of $1.54 billion, a price-to-earnings ratio of -128.64 and a beta of 0.49. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. The company’s 50-day moving average price is $64.46 and its two-hundred day moving average price is $59.99. ANI Pharmaceuticals, Inc. has a 52 week low of $52.50 and a 52 week high of $71.85.

Insider Buying and Selling at ANI Pharmaceuticals

In other news, SVP Krista Davis sold 1,000 shares of ANI Pharmaceuticals stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $60.20, for a total value of $60,200.00. Following the transaction, the senior vice president now owns 68,624 shares of the company’s stock, valued at $4,131,164.80. The trade was a 1.44 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, VP Meredith Cook sold 400 shares of ANI Pharmaceuticals stock in a transaction that occurred on Monday, April 14th. The stock was sold at an average price of $68.96, for a total transaction of $27,584.00. Following the completion of the transaction, the vice president now directly owns 80,145 shares in the company, valued at $5,526,799.20. This represents a 0.50 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 3,200 shares of company stock valued at $197,792. Company insiders own 12.70% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.